Diagnostic value of anti-Mullerian hormone in adolescent girls with polycystic ovary syndrome

Authors

DOI:

https://doi.org/10.22141/2224-0721.18.3.2022.1164

Keywords:

adolescent girls, anti-Mullerian hormone, polycystic ovary syndrome

Abstract

Background. Scientific debate continues on the diagnostic criteria for polycystic ovary syndrome in adolescents (PCOS). In adolescents these criteria cause special diagnostic problems due to the fact that the characteristics of normal puberty often coincide with the signs and symptoms of PCOS. There is a need to develop diagnostic criteria for PCOS in adolescents, which could be used in addition to those proposed. A possible additional diagnostic criterion may be the level of anti-Mullerian hormone (AMH). The purpose of the study is to assess the levels of anti-Mullerian hormone in the blood of adolescent girls with polycystic ovary syndrome. Materials and methods. A clinical-anamnestic and laboratory study of 27 adolescent girls (12–18 years) with PCOS was conducted. The comparison group consisted of 25 girls of the same age without gynecological disorders. Determination of AMG was performed in venous serum (Gen II ELISA, Beckman Coulter). Results. The anamnesis of adolescent girls with PCOS was analyzed: intrauterine hypoxia occurred in almost half of adolescents, pathological course of the postnatal period was observed in 25.9 %, infectious index was 4.6, hypertensive-hydrocephalic syndrome was found in 23.8 %, minimal cerebral dysfunction 28.5 %, autonomic disorders — in 47.6 %, most of the surveyed girls had average body weight and height, inverted puberty and disharmonious sexual development. The most common symptoms of PCOS in girls were: hypomenstrual syndrome (86.9 %), dermopathy (82.6 %) and hirsutism (60.8 %). The mean AMG in girls with PCOS and in the compari­son group was 3.67 ± 1.0 ng/ml (in girls with PCOS 4.8 ± 0.9 and in girls in the comparison group 3.1 ± 0.7 ng/ml, p < 0.05). Adolescent girls with form A PCOS had the highest hormone levels — 6.4 [4.8; 6.9] pg/ml, p < 0.01, which may indicate a probable diagnostic value of AMG concentration. Conclusions. Adolescent girls with suspected polycystic ovary syndrome should have a complete set of tests to determine the level of anti-Mullerian hormone as an additional marker, especially in the absence of clinical manifestations of hyperandrogenemia.

Downloads

Download data is not yet available.

References

Mills MC, Tropf FC, Brazel DM, et al. Identification of 371 genetic variants for age at first sex and birth linked to externalising behaviour. Nat Hum Behav. 2021 Dec;5(12):1717-1730. doi: 10.1038/s41562-021-01135-3.

Sadeeqa S, Mustafa T, Latif S. Polycystic Ovarian Syndrome-Related Depression in Adolescent Girls: A Review. J Pharm Bioallied Sci. 2018;10(2):55-59. doi: 10.4103/JPBS.JPBS_1_18.

Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467-520. doi: 10.1210/er.2015-1104.

National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome. Bethesda, Maryland: NIH; 2012. 

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7. doi: 10.1093/humrep/deh098.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25. doi: 10.1016/j.fertnstert.2003.10.004.

Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009;116(12):1633-9. doi: 10.1111/j.1471-0528.2009.02347.x.

Azziz R, Carmina E, Dewailly D, et al.; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88. doi: 10.1016/j.fertnstert.2008.06.035.

Sultan C, Paris F. Clinical expression of polycystic ovary syndrome in adolescent girls. Fertil Steril. 2006;86 Suppl 1:S6. doi: 10.1016/j.fertnstert.2006.04.015.

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015;36(5):487-525. doi:10.1210/er.2015-1018.

Rudnicka E, Kunicki M, Calik-Ksepka A, et al. Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS. Int J Mol Sci. 2021;22(22):12507. doi: 10.3390/ijms222212507.

Silva MSB, Giacobini P. New insights into anti-Müllerian hormone role in the hypothalamic-pituitary-gonadal axis and neuroendocrine development. Cell Mol Life Sci. 2021;78(1):1-16. doi:10.1007/s00018-020-03576-x.

Caanen MR, Peters HE, van de Ven PM, et al. Anti-Müllerian Hormone Levels in Adolescence in Relation to Long-term Follow-up for Presence of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021;106(3):e1084-e1095. doi: 10.1210/clinem/dgaa949.

Abbott DH, Dumesic DA, Levine JE. Hyperandrogenic origins of polycystic ovary syndrome – implications for pathophysiology and therapy. Expert Rev Endocrinol Metab. 2019;14(2):131-143. doi:10.1080/17446651.2019.1576522.

Yates AP, Jopling HM, Burgoyne NJ, Hayden K, Chaloner CM, Tetlow L. Paediatric reference intervals for plasma anti-Müllerian hormone: comparison of data from the Roche Elecsys assay and the Beckman Coulter Access assay using the same cohort of samples. Ann Clin Biochem. 2019;56(5):536-547. doi:10.1177/0004563219830733.

Abdolahian S, Tehrani FR, Amiri M, et al. Effect of lifestyle modifications on anthropometric, clinical, and biochemical parameters in adolescent girls with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Endocr Disord. 2020;20(1):71. doi:10.1186/s12902-020-00552-1.

Sadeghi HM, Adeli I, Calina D, et al. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022;23(2):583. doi: 10.3390/ijms23020583.

Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pac J Cancer Prev. 2017;18(1):17-21. doi:10.22034/APJCP.2017.18.1.17.

Rao P, Bhide P. Controversies in the diagnosis of polycystic ovary syndrome. Ther Adv Reprod Health. 2020;14:2633494120913032. doi:10.1177/2633494120913032.

Kim KW. Unravelling Polycystic Ovary Syndrome and Its Comorbidities. J Obes Metab Syndr. 2021;30(3):209-221. doi:10.7570/jomes21043.

Mimouni NEH, Paiva I, Barbotin AL, et al. Polycystic ovary syndrome is transmitted via a transgenerational epigenetic process. Cell Metab. 2021;33(3):513-530.e8. doi:10.1016/j.cmet.2021.01.004.

Cutillas-Tolín A, Arense-Gonzalo JJ, Mendiola J, et al. Are Dietary Indices Associated with Polycystic Ovary Syndrome and Its Phenotypes? A Preliminary Study. Nutrients. 2021;13(2):313. doi:10.3390/nu13020313.

Rudnicka E, Kunicki M, Calik-Ksepka A. Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS. Int J Mol Sci. 2021;22(22):12507. doi:10.3390/ijms222212507.

Owens LA, Kristensen SG, Lerner A. et al. Gene Expression in Granulosa Cells From Small Antral Follicles From Women With or Without Polycystic Ovaries. J Clin Endocrinol Metab. 2019;104(12):6182-6192. doi:10.1210/jc.2019-00780.

Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007 Jan;92(1):240-5. doi: 10.1210/jc.2006-1582.

Guedikian AA, Lee AY, Grogan TR, et al. Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome. Fertil Steril. 2018;109(3):508-515. doi:10.1016/j.fertnstert.2017.11.017.

Xing C, Zhang J, Zhao H, He B. Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment. Int J Womens Health. 2022;14:91-105. doi:10.2147/IJWH.S344542.

Ran Y, Yi Q, Li C. The Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients with Different Subgroups. Diabetes Metab Syndr Obes. 2021;14:1419-1424. doi:10.2147/DMSO.S299558.

Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med. 2018;24(6):834-846. doi:10.1038/s41591-018-0035-5.

Kanakatti Shankar R, Dowlut-McElroy T, Dauber A, Gomez-Lobo V. Clinical Utility of Anti-Mullerian Hormone in Pediatrics. J Clin Endocrinol Metab. 2022;107(2):309-323. doi:10.1210/clinem/dgab687.

Zhou S, Lu D, Wen S, Sheng Y, Kang D, Xu L. Elevated Anti-Müllerian Hormone Levels in Newborns of Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis Based on Observational Studies. Reprod Sci. 2022;29(1):301-311. doi:10.1007/s43032-021-00652-w.

Ahmed N, Batarfi AA, Bajouh OS, Bakhashab S. Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms. Diagnostics (Basel). 2019;9(4):136. doi:10.3390/diagnostics9040136.

Gorsic LK, Kosova G, Werstein B, et al. Pathogenic Anti-Müllerian Hormone Variants in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017;102(8):2862-2872. doi:10.1210/jc.2017-00612.

Sahmay S, Atakul N, Aydogan B, Aydin Y, Imamoglu M, Seyisoglu H. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2013 Dec;92(12):1369-74. doi: 10.1111/aogs.12247.

Owens LA, Kristensen SG, Lerner A, et al. Gene Expression in Granulosa Cells From Small Antral Follicles From Women With or Without Polycystic Ovaries. J Clin Endocrinol Metab. 2019;104(12):6182-6192. doi:10.1210/jc.2019-00780.

Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Mar;91(3):941-5. doi: 10.1210/jc.2005-2076.

Dewailly D, Barbotin AL, Dumont A, Catteau-Jonard S, Robin G. Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2020;11:641. doi:10.3389/fendo.2020.00641.

Hagen CP, Aksglaede L, Sørensen K, et al. Individual levels of antimullerian hormone in the serum of healthy girls are maintained in childhood and adolescence: a longitudinal cohort study. Hum Reprod. 2012;27(3):861-866. doi: 10.1093/humrep/der435.

Hart R, Doherty DA, Norman RJ, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010;94(3):1118-21. doi: 10.1016/j.fertnstert.2009.11.002.

Song DK, Oh JY, Lee H, Sung YA. Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value. Korean J Intern Med. 2017;32(4):690-698. doi:10.3904/kjim.2016.038.

Published

2022-06-29

How to Cite

Sorokman, T., Makarova, O., & Ostapchuk, V. (2022). Diagnostic value of anti-Mullerian hormone in adolescent girls with polycystic ovary syndrome. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 18(3), 163–168. https://doi.org/10.22141/2224-0721.18.3.2022.1164

Issue

Section

Original Researches

Most read articles by the same author(s)

1 2 3 > >>